ERBB2 and breast carcinoma: Many previous studies suggested that HER2-low breast cancer may be a clinically and biologically distinct subtype that may affect patient prognosis (17), and for early-stage breast carcinoma patients, a low HER2 level can negatively affect prognosis even without HER2 amplification (10, 18–21).